Servier hit by bone drug safety issues as Mediator continues to make waves
This article was originally published in Scrip
Executive Summary
The French company Servier, already staggering under the weight of the Mediator affair, is again under fire, this time over the safety profile of its osteoporosis drug, Protelos (strontium ranelate). A French committee is examining the pharmacovigilance data on the product to see whether its risk-benefit profile needs to change, and Servier's pharmacovigilance systems are also under the spotlight.
You may also be interested in...
Denmark Planning To Impose Drug Stockpiling Obligations From July
A new bill is intended to address the increase in medicine supply problems in Denmark in recent years.
National Drug Stockpiles Create ‘False Sense Of Security’
The generics and biosimilars industry body Medicines for Europe says disparate national stockpiling requirements are not a solution to shortages and can bring “significant risks” for the supply chain and access to medicines.
UK Explains New Rules On Parallel Imports From EU
Guidance from the Medicines and Healthcare products Regulatory Agency says that the packaging of parallel imported medicines must make clear that they are for the UK market only.